Floatz logo

Daunorubicin

Acute Leukemia of Ambiguous Lineage

SWOG Cancer Research NetworkPhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

45 Active assets in the Acute Leukemia of Ambiguous Lineage cohort.

Asset / SponsorPhaseRating
L-Ofloxacin
Children's Oncology Group
Phase 3BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
METHOTREXATE
SWOG Cancer Research Network
Phase 2B
Cytosin-Arabinosid
SWOG Cancer Research Network
Phase 2B
VINCRISTINE SULFATE
Children's Oncology Group
Phase 2B

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →